Physician profile
Ryan B Rich
NPI 1578852455
$5,233.62
in general payments reported to CMS, 2019-2025
33 companies · $629 in 2025
The $629 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,380 · 2020: $455 · 2021: $123 · 2022: $380 · 2023: $408 · 2024: $858 · 2025: $629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,756 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,756.38 |
| Education | $139.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $940.68 | 2019-2025 | |
| Genzyme Corporation | $393.54 | 2019-2025 | |
| Ucb, INC. | $393.30 | 2019-2024 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $361.83 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $262.38 | 2019-2020 | |
| Janssen Biotech, INC. | $255.95 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Galderma Laboratories, L.P. | $243.69 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $226.05 | 2019-2024 | Dupixent |
| Sun Pharmaceutical Industries INC. | $225.88 | 2019-2025 | |
| Allergan, INC. | $210.86 | 2019-2022 | |
| Almirall LLC | $207.37 | 2019-2022 | |
| Pfizer INC. | $196.40 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $191.78 | 2019-2020 | |
| Amgen INC. | $191.30 | 2019-2024 | Otezla |
| Merz North America, INC. | $168.05 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $151.83 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $84.36 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.95 | 2022-2024 | Spevigo |
| Epi Health, LLC | $71.62 | 2019-2020 | |
| Biofrontera INC. | $48.53 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $39.61 | 2023-2025 | Sotyktu |
| Celgene Corporation | $37.86 | 2019 | |
| Vyne Pharmaceuticals INC. | $36.01 | 2020 | |
| Journey Medical Corporation | $34.40 | 2019 | |
| Aclaris Therapeutics, INC. | $31.36 | 2019 | |
| Convatec INC. | $28.43 | 2025 | |
| Incyte Corporation | $27.82 | 2024 | Opzelura |
| Organogenesis INC. | $25.21 | 2021 | |
| Mimedx Group, INC. | $17.90 | 2024 | |
| Dusa Pharmaceuticals, INC. | $15.89 | 2019 | |
| Dermira, INC. | $15.44 | 2019 | |
| Kerecis Limited | $14.34 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Glenmark Therapeutics INC. | $5.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Rich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.